Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jun;63(6):930–932. doi: 10.1038/bjc.1991.203

Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle.

P Mullen 1, W N Scott 1, W R Miller 1
PMCID: PMC1972522  PMID: 1906293

Full text

PDF
930

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blankenstein M. A., Henkelman M. S., Klijn J. G. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1493–1499. doi: 10.1016/0277-5379(85)90244-5. [DOI] [PubMed] [Google Scholar]
  2. Butler W. B., Berlinski P. J., Hillman R. M., Kelsey W. H., Toenniges M. M. Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7. Cancer Res. 1986 Dec;46(12 Pt 1):6339–6348. [PubMed] [Google Scholar]
  3. Eidne K. A., Flanagan C. A., Millar R. P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science. 1985 Sep 6;229(4717):989–991. doi: 10.1126/science.2992093. [DOI] [PubMed] [Google Scholar]
  4. Fekete M., Wittliff J. L., Schally A. V. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal. 1989;3(3):137–147. doi: 10.1002/jcla.1860030302. [DOI] [PubMed] [Google Scholar]
  5. Fraser H. M. A new class of contraceptives? Nature. 1982 Apr 1;296(5856):391–392. doi: 10.1038/296391a0. [DOI] [PubMed] [Google Scholar]
  6. Fraser H. M., Baird D. T. Clinical applications of LHRH analogues. Baillieres Clin Endocrinol Metab. 1987 Feb;1(1):43–70. doi: 10.1016/s0950-351x(87)80052-6. [DOI] [PubMed] [Google Scholar]
  7. Klijn J. G., de Jong F. H., Blankenstein M. A., Docter R., Alexieva-Figusch J., Blonk-van der Wijst J., Lamberts S. W. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer. Breast Cancer Res Treat. 1984;4(3):209–220. doi: 10.1007/BF01806487. [DOI] [PubMed] [Google Scholar]
  8. Manni A., Santen R., Harvey H., Lipton A., Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev. 1986 Feb;7(1):89–94. doi: 10.1210/edrv-7-1-89. [DOI] [PubMed] [Google Scholar]
  9. Miller W. R., Scott W. N., Morris R., Fraser H. M., Sharpe R. M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985 Jan 17;313(5999):231–233. doi: 10.1038/313231a0. [DOI] [PubMed] [Google Scholar]
  10. Plowman P. N., Nicholson R. I., Walker K. J. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer. 1986 Dec;54(6):903–909. doi: 10.1038/bjc.1986.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Scambia G., Panici P. B., Baiocchi G., Perrone L., Gaggini C., Iacobelli S., Mancuso S. Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Anticancer Res. 1988 Jan-Feb;8(1):187–190. [PubMed] [Google Scholar]
  12. Slotman B. J., Poels L. G., Rao B. R. A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment. Anticancer Res. 1989 Jan-Feb;9(1):77–80. [PubMed] [Google Scholar]
  13. Vindeløv L. L., Christensen I. J., Keiding N., Spang-Thomsen M., Nissen N. I. Long-term storage of samples for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):317–322. doi: 10.1002/cyto.990030502. [DOI] [PubMed] [Google Scholar]
  14. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  15. Walker K. J., Turkes A., Williams M. R., Blamey R. W., Nicholson R. I. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer. J Endocrinol. 1986 Nov;111(2):349–353. doi: 10.1677/joe.0.1110349. [DOI] [PubMed] [Google Scholar]
  16. Waxman J. H., Harland S. J., Coombes R. C., Wrigley P. F., Malpas J. S., Powles T., Lister T. A. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol. 1985;15(2):171–173. doi: 10.1007/BF00257531. [DOI] [PubMed] [Google Scholar]
  17. Wilding G., Chen M., Gelmann E. P. LHRH agonists and human breast cancer cells. 1987 Oct 29-Nov 4Nature. 329(6142):770–770. doi: 10.1038/329770a0. [DOI] [PubMed] [Google Scholar]
  18. Williams M. R., Walker K. J., Turkes A., Blamey R. W., Nicholson R. I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 1986 May;53(5):629–636. doi: 10.1038/bjc.1986.106. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES